{"id":20072,"date":"2026-06-12T04:00:00","date_gmt":"2026-06-12T02:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=aaaa9984e6a8fdccd02c20317850a84d"},"modified":"2026-06-12T04:00:00","modified_gmt":"2026-06-12T02:00:00","slug":"investor-alert-securities-class-action-filed-against-adma-biologics-inc-investors-encouraged-to-contact-kirby-mcinerney-llp","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=20072","title":{"rendered":"INVESTOR ALERT: Securities Class Action Filed Against ADMA Biologics, Inc. \u2013 Investors Encouraged to Contact Kirby McInerney LLP"},"content":{"rendered":"

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP<\/a> announces that a class action lawsuit has been filed on behalf of investors who acquired ADMA Biologics, Inc. (\u201cADMA\u201d or the \u201cCompany\u201d) (NASDAQ:ADMA) securities during the period of August 9, 2024 through March 25, 2026, inclusive (\u201cthe Class Period\u201d).<\/p>

If you suffered a loss on your ADMA investments, you have until August 10, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadline. If you choose to take no action, you may remain an absent class member. For more information about the lawsuit:<\/p>

[CONTACT THE FIRM IF YOU SUFFERED A LOSS<\/a>]<\/p>

What Is This Lawsuit About? <\/b>The lawsuit alleges that (1) ADMA engaged in an undisclosed related party transaction; (2) ADMA used channel stuffing to create an appearance of revenue; and (3) ADMA lacked adequate internal controls.<\/p>

On March 24, 2026, Culper Research published a short seller report on ADMA alleging \u201cChannel Stuffing, an Undisclosed Related Party Distributor, and \u20133% Real Growth in 2025 vs. +20% Reported.\u201d Among other things, the report stated that \u201ctwo high-level employees at one of ADMA's two largest distributors,\u201d had confirmed independently that \u201cstarting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations. Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there.\u201d On this news, the price of ADMA shares declined by $2.26 per share, or approximately 17%, from $13.59 per share on March 23, 2026 to close at $11.33 on March 24, 2026. The price of ADMA shares declined further by $1.70 per share, or approximately 15%, from $11.33 on March 24, 2026 to close at $9.63 on March 25, 2026.<\/p>

On March 26, 2026, Investing.com published an article that reported \u201cCantor Fitzgerald downgraded ADMA \u2026 following pressure on the shares from a short report alleging the company is boosting ASCENIV revenues through channel stuffing \u2026 Cantor Fitzgerald said it expected more specific feedback addressing the direct claims in the short report. Cantor Fitzgerald said the lack of clarity makes it difficult to recommend investors take advantage of stock weakness \u2026 The firm said investors are looking for a more thoughtful response from the company and want ADMA Biologics to address cash flow inconsistencies. On this news, the price of ADMA shares declined by $1.34 per share, or approximately 14%, from $9.63 per share on March 25, 2026 to close at $8.29 on March 26, 2026.<\/p>

[LEARN MORE ABOUT THE LAWSUIT<\/a>]<\/p>

The Lead Plaintiff Appointment Process. <\/b>The federal securities laws permit any investor who acquired eligible securities during the class period to seek appointment as lead plaintiff in a <\/i>class action lawsuit. Courts typically appoint the investor(s) with the largest financial loss in the case and the ability to represent the class rather than investors with simply the largest investment portfolio. Courts regularly appoint individual investors, whether acting alone or as a group, as lead plaintiffs. The rights of any investor who bought shares during the class period are generally already protected. However, lead plaintiffs have the power to influence case strategy and have a say in settlement decisions, as well as decisions concerning allocation of settlement funds among class members.<\/p>

[LEARN MORE ABOUT THE LEAD PLAINTIFF PROCESS<\/a>]<\/p>

What Should I Do? <\/b>If you purchased or otherwise acquired ADMA securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro<\/a> of Kirby McInerney LLP<\/a> by email at investigations@kmllp.com<\/a>, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.<\/p>

Kirby McInerney LLP<\/a> is a New York-based plaintiffs\u2019 law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm\u2019s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP\u2019s website<\/a>.<\/p>

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p><\/a><\/a> Contacts<\/b>

Kirby McInerney LLPLauren Molinaro, Esq.212-699-1171https:\/\/www.kmllp.com<\/a>https:\/\/securitiesleadplaintiff.com\/<\/a>investigations@kmllp.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ADMA Biologics, Inc. (\u201cADMA\u201d or the \u201cCompany\u201d) (NASDAQ:ADMA) securities during the period of August …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-20072","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20072"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20072\/revisions"}],"predecessor-version":[{"id":20073,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20072\/revisions\/20073"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}